Cas:9017-68-9 6-methylheptyl prop-2-enoate,prop-2-enoic acid manufacturer & supplier

Chemical Name:6-methylheptyl prop-2-enoate,prop-2-enoic acid

CAS.NO:9017-68-9

Synonyms:prop-2-enoic acid-6-methylheptyl prop-2-enoate(1:1);2-Propenoic acid,polymer with isooctyl 2-propenoate

Molecular Formula:C₁₄H₂₄O₄

Molecular Weight:256.33800

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:227.7ºC at 760mmHg

Density:N/A

Index of Refraction:

PSA:63.60000

Exact Mass:256.16700

LogP:3.18900

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like prop-2-enoic acid-6-methylheptyl prop-2-enoate(1:1) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Propenoic acid,polymer with isooctyl 2-propenoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Propenoic acid,polymer with isooctyl 2-propenoate Use and application,prop-2-enoic acid-6-methylheptyl prop-2-enoate(1:1) technical grade,usp/ep/jp grade.

Related News: You will find the name and amount of the active ingredient contained in the medicine on the package of OTC (over-the-counter) drugs. 6-methylheptyl prop-2-enoate,prop-2-enoic acid manufacturer Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country. 6-methylheptyl prop-2-enoate,prop-2-enoic acid supplier In a stringent xenograft model of disseminated lymphoblastic leukemia, FT819 demonstrated enhanced tumor clearance and control of leukemia as compared to primary CAR19 T cells. 6-methylheptyl prop-2-enoate,prop-2-enoic acid vendor In a stringent xenograft model of disseminated lymphoblastic leukemia, FT819 demonstrated enhanced tumor clearance and control of leukemia as compared to primary CAR19 T cells. 6-methylheptyl prop-2-enoate,prop-2-enoic acid factory Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country.